S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies
TL;DR: This review provides a comprehensive overview of the abnormalities in the PI3K/AKT/mTOR signaling pathway in pediatric hematologic malignancies, the agents that are used to target this pathway, and the results of preclinical and clinical trials, using those agents in childhood hematological cancers.
Journal ArticleDOI
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
TL;DR: The efficacy of the RNA CAR infusions may approach that of stably expressed CARs, offer theoretically safer initial clinical testing in addition to suicide systems, and allow for rapid and effective iterative preclinical modeling for the testing of new targets.
Journal ArticleDOI
Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia
Amanda M. Li,George E Hucks,Amanda M. DiNofia,Alix E. Seif,David T. Teachey,Diane Baniewicz,Colleen Callahan,Christina Fasano,Beth McBride,Vanessa E. Gonzalez,Farzana Nazimuddin,David L. Porter,Simon F. Lacey,Carl H. June,Stephan A. Grupp,Shannon L. Maude +15 more
TL;DR: P promising responses were specifically seen in those with early B-cell recovery and bulky extramedullary disease, suggesting a different mechanism such as AICD may be responsible for poor initial responses.
Journal ArticleDOI
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Michael A. Pulsipher,Bryan Langholz,Donna A. Wall,Kirk R. Schultz,Nancy Bunin,William L. Carroll,Elizabeth A. Raetz,Sharon Gardner,Julie M. Gastier-Foster,Denise L. Howrie,Rakesh K. Goyal,James G. Douglas,Michael J. Borowitz,Y. Barnes,David T. Teachey,Candace Taylor,Stephan A. Grupp +16 more
TL;DR: Although addition of sirolimus decreased aGVHD, survival was not improved, and multivariate analysis showed increased relapse risk in children with ≥0.1% minimal residual disease (MRD) pretransplant, and decreased risk in patients with grades 1-3 aGV HD (P = .04).
Journal ArticleDOI
Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003.
Michael A. Pulsipher,John E. Levine,Robert J. Hayashi,Kawah Chan,Phillip A. Anderson,Reggie E. Duerst,I. Osunkwo,V. Fisher,Biljana Horn,Stephan A. Grupp +9 more
TL;DR: This experience with over 200 collections demonstrates that PBSC collection is safe in normal pediatric donors and desired CD34 cell yields are easily achieved.